FDA approved Aurinia Pharmaceuticals LUPKYNIS (voclosporin) for adults with active lupus nephritis

, , , ,

On Jan. 22, 2021, Aurinia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA)  had approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN).

LUPKYNIS was the first FDA-approved oral therapy for LN which causes irreversible kidney damage and significantly increases the risk of kidney failure, cardiac events, and death.

Tags:


Source: Aurinia Pharmaceuticals
Credit: